gsk201107146k.htm
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending July 2011
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of an increase in interests in Ordinary shares in GlaxoSmithKline plc purchased at a price of 1367.69 pence per share on 13 July 2011, in respect of the personal holdings of the under-mentioned persons
following the re-investment of the dividend paid to shareholders on 7 July 2011.
| |
Ordinary shares
|
|
Mr A P Witty
|
10.015
|
|
Dr M M Slaoui
|
151.497
|
|
Mr S M Bicknell
|
24.793
|
|
Mr J M Clarke
|
567.855
|
|
Mr M Dunoyer
|
95.346
|
|
Mr E J Gray
|
335.799
|
|
Mr S A Hussain
|
211.502
|
|
Mr D S Redfern
|
151.613
|
|
Mr J R Stéphenne
|
637.670
|
|
Ms C Thomas
|
114.613
|
|
Mr P C Thomson
|
79.836
|
|
Dr P J T Vallance
|
96.499
|
The Company was advised of this information on 14 July 2011.
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
14 July 2011
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: July 14, 2011
By: VICTORIA WHYTE
------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc